| Study | Exclusion reasons | Rmk | Reference |
|---|---|---|---|
| Brock-Utne, 1980 | not relevant outcome | EXCLUDED: efficacy (no data on safety of fetus, neonate and/or parturiente). | |
| Benevent, 2019 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Atropinic drugs analyzed as a whole without distinction between treatments. |
Benevent Fundam Clin Pharmacol 2019; 33:314-326 10.1111/fcp.12428 |
| Beau, 2016 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Atropinic drugs analyzed as a whole without distinction between treatments. | |
| Banhidy, 2007 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis according to illness status, without distinction between treatments. |
Banhidy Eur. J. Obstet. Gynecol. Reprod. Biol. 2007; 134:157-63 10.1016/j.ejogrb.2006.08.025 |
| Bérard, 2019 | pattern of exposure | EXCLUDED: Pattern of exposure. Pregnancy outcome (delivery, spontaneous or induced/plannedabortions) described according medication use as a whole. |
Bérard PLoS ONE 2019; 14:e0219095 10.1371/journal.pone.0219095 |
| Baraka, 2013 | pattern of exposure | EXCLUDED: study on pattern of exposure without data on fetal/maternal/neonatal safety. |
Baraka J. Matern. Fetal. Neonatal. Med. 2013; 26:900-7 10.3109/14767058.2013.765843 |